Ado-Trastuzumab Emtansine
Showing 1 - 25 of 1,045
Ado-trastuzumab Emtansine-Induced Peripheral Neuropathy in
Recruiting
- Breast Neoplasm
-
Rochester, MinnesotaMayo Clinic Minnesota
Jun 12, 2023
Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)
Not yet recruiting
- Metastatic Solid Tumor
- Brain Metastases
- Trastuzumab emtansine
- Tucatinib
-
Houston, TexasM D Anderson Cancer Center
Dec 30, 2022
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial
Recruiting
- Metastatic Salivary Gland Carcinoma
- +4 more
- Docetaxel
- +3 more
-
New York, New YorkMemorial Sloane Kettering Cancer Center
Jan 11, 2023
Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,
Recruiting
- Salivary Gland Cancer
- HER2 Gene Mutation
- Ado-trastuzumab (T) emtansine (T-DM1)
- +2 more
-
Boston, Massachusetts
- +1 more
Jan 2, 2023
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,
Completed
- HER2 Positive Breast Carcinoma
- +6 more
- Utomilumab
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 22, 2022
Solid Tumor Cancers, Lung Cancer, Bladder Cancer Trial in United States (ado-trastuzumab emtansine)
Recruiting
- Solid Tumor Cancers
- +3 more
- ado-trastuzumab emtansine
-
Basking Ridge, New Jersey
- +6 more
Mar 1, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Withdrawn
- Anatomic Stage IV Breast Cancer AJCC v8
- +3 more
- Abemaciclib
- Trastuzumab Emtansine
-
Yuma, Arizona
- +5 more
May 25, 2022
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer Trial run by the NCI (Brachyury-TRICOM, Entinostat, M7824)
Terminated
- Breast Cancer
- +4 more
- Brachyury-TRICOM
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 9, 2021
Breast Cancer Trial in United States (HKI-272, Surgical Resection, Capecitabine)
Active, not recruiting
- Breast Cancer
- HKI-272
- +3 more
-
San Francisco, California
- +17 more
Jan 30, 2023
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States
Recruiting
- Breast Adenocarcinoma
- +7 more
- Multi-epitope HER2 Peptide Vaccine TPIV100
- +5 more
-
Scottsdale, Arizona
- +26 more
Aug 17, 2022
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,
Not yet recruiting
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- SHR-A1811
- Trastuzumab Emtansine
- (no location specified)
Nov 7, 2023
Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer Trial in Canada, Mexico, Spain (drug, procedure,
Recruiting
- Early Breast Cancer
- +2 more
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
- +6 more
-
Buenos Aires, Argentina
- +29 more
Jan 31, 2023
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
Trastuzumab Emtansine as Therapy in Chinese HER2 Positive
Not yet recruiting
- Breast Cancer
- Trastuzumab emtansine
- (no location specified)
Jul 13, 2023
HER2 Positive Breast Cancers Trial in Canada, United States (Tucatinib (ONT-380), T-DM1)
Completed
- HER2 Positive Breast Cancers
- Tucatinib (ONT-380)
- T-DM1
-
Birmingham, Alabama
- +10 more
Sep 17, 2020
NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Trastuzumab emtansine
- Osimertinib
-
Maastricht, Limburg, Netherlands
- +4 more
Nov 7, 2022
Breast Cancer, Heart Failure Trial in Canada, Russian Federation (Trastuzumab, Pertuzumab, Trastuzumab emtansine)
Recruiting
- Breast Cancer
- Heart Failure
- Trastuzumab
- +2 more
-
Hamitlon, Ontario, Canada
- +3 more
Jun 21, 2022
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate
Not yet recruiting
- HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
- Trastuzumab Emtansine for Injection
- Pyrotinib Maleate Tablets
- (no location specified)
Sep 30, 2022
HER2-positive Breast Cancer, Breast Cancer Metastatic Trial in Kansas City, Overland Park, Lee's Summit (Palbociclib 75mg,
Active, not recruiting
- HER2-positive Breast Cancer
- Breast Cancer Metastatic
- Palbociclib 75mg
- +5 more
-
Kansas City, Kansas
- +4 more
Nov 23, 2020
Breast Tumors, Malignant Tumor of the Breast Trial in Multiple Locations (Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel,
Terminated
- Breast Neoplasms
- Malignant Tumor of the Breast
- Trastuzumab
- +2 more
-
Multiple Locations, Texas19 Sites
Nov 29, 2022
Trastuzumab Emtansine in HER2-positive Breast Cancer Residual
Recruiting
- Breast Cancer
- Trastuzumab emtansine
-
Prato, Firenze, Italy
- +27 more
Mar 2, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma Trial in
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +14 more
- Biopsy
- +25 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2022